Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features

References

• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354:1813-26; PMID:16641398; https://doi.org/10.1056/NEJMra052638
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411:385-9; PMID:11357147; https://doi.org/10.1038/35077251
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112:4371-83; PMID:19029455; https://doi.org/10.1182/blood-2008-03-077974
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-62; PMID:2297567.
   PubMed Web of Science ®Google Scholar
• Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008; 142:877-88; PMID:18564358; https://doi.org/10.1111/j.1365-2141.2008.07260.x
   PubMed Web of Science ®Google Scholar
• Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100:3108-14; PMID:12384406; https://doi.org/10.1182/blood-2002-02-0506
   PubMed Web of Science ®Google Scholar
• Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2014; 20:1785-90; PMID:25034960; https://doi.org/10.1016/j.bbmt.2014.07.010
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-61; PMID:19282026; https://doi.org/10.1016/S0140-6736(09)60237-3
   PubMed Web of Science ®Google Scholar
• Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev 2003; 17:187-94; PMID:14556773
   PubMed Web of Science ®Google Scholar
• Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: How do they pull the trigger? Immunology 2009; 128:7-15; PMID:19689731; https://doi.org/10.1111/j.1365-2567.2009.03123.x
   PubMed Web of Science ®Google Scholar
• Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214:73-91; PMID:17100877; https://doi.org/10.1111/j.1600-065X.2006.00457.x
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94:333-9; PMID:10381530
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100; PMID:11896281; https://doi.org/10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value. Blood 2007; 110:433-40; PMID:17371948; https://doi.org/10.1182/blood-2006-07-038687
   PubMed Web of Science ®Google Scholar
• Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010; 115:4293-301; PMID:20233969; https://doi.org/10.1182/blood-2009-05-222190
   PubMed Web of Science ®Google Scholar
• Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Loffler H, Müller-Ruchholtz W. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model. Bone Marrow Transplant 1993; 12(Suppl 3):S57-60; PMID:8124260
   PubMed Web of Science ®Google Scholar
• Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 2011; 3:1445-59; PMID:22091681; https://doi.org/10.2217/imt.11.131
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17:1025-36; PMID:27540992; https://doi.org/10.1038/ni.3518
   PubMed Web of Science ®Google Scholar
• Locatelli F, Moretta F, Brescia L, Merli P. Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol 2014; 26:173-9; PMID:24613727; https://doi.org/10.1016/j.smim.2014.02.004
   PubMed Web of Science ®Google Scholar
• Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: Effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant 2009; 15:765-76; PMID:19539207; https://doi.org/10.1016/j.bbmt.2009.01.019
   PubMed Web of Science ®Google Scholar
• Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, Bourhis JH, Spanholtz J. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol 2014; 5:95; PMID:24672522; https://doi.org/10.3389/fimmu.2014.00095
   PubMed Web of Science ®Google Scholar
• Koepsell SA, Miller JS, McKenna DH Jr. Natural killer cells: A review of manufacturing and clinical utility. Transfusion 2013; 53:404-10; PMID:22670662; https://doi.org/10.1111/j.1537-2995.2012.03724.x
   PubMed Web of Science ®Google Scholar
• Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005; 22:295-304; PMID:15780987; https://doi.org/10.1016/j.immuni.2005.01.013
   PubMed Web of Science ®Google Scholar
• Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood 1992; 80:2182-7; PMID:1384796
   PubMed Web of Science ®Google Scholar
• Luevano M, Madrigal A, Saudemont A. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol 2012; 9:310-20; PMID:22705914; https://doi.org/10.1038/cmi.2012.17
   PubMed Web of Science ®Google Scholar
• Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87:2632-40; PMID:8639878
   PubMed Web of Science ®Google Scholar
• Kao IT, Yao CL, Kong ZL, Wu ML, Chuang TL, Hwang SM. Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells. Stem Cells Dev 2007; 16:1043-51; PMID:17999637; https://doi.org/10.1089/scd.2007.0033
   PubMed Web of Science ®Google Scholar
• Luevano M, Domogala A, Blundell M, Jackson N, Pedroza-Pacheco I, Derniame S, Escobedo-Cousin M, Querol S, Thrasher A, Madrigal A, et al. Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells. PloS One 2014; 9:e87086; PMID:24489840; https://doi.org/10.1371/journal.pone.0087086
   PubMed Web of Science ®Google Scholar
• Vasu S, Berg M, Davidson-Moncada J, Tian X, Cullis H, Childs RW. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy 2015; 17:1582-93; PMID:26432560; https://doi.org/10.1016/j.jcyt.2015.07.020
   PubMed Web of Science ®Google Scholar
• Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PloS One 2010; 5:e9221; PMID:20169160; https://doi.org/10.1371/journal.pone.0009221
   PubMed Web of Science ®Google Scholar
• Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, de Vries J, Boerman O, Schaap N, van der Voort R, Spanholtz J, et al. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PloS One 2013; 8:e64384; PMID:23755121; https://doi.org/10.1371/journal.pone.0064384
   PubMed Web of Science ®Google Scholar
• Ayello J, van de Ven C, Fortino W, Wade-Harris C, Satwani P, Baxi L, Simpson LL, Sanger W, Pickering D, Kurtzberg J, et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant 2006; 12:608-22; PMID:16737934; https://doi.org/10.1016/j.bbmt.2006.01.009
   PubMed Web of Science ®Google Scholar
• Amsellem S, Pflumio F, Bardinet D, Izac B, Charneau P, Romeo PH, Dubart-Kupperschmitt A, Fichelson S. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat Med 2003; 9:1423-7; PMID:14578882; https://doi.org/10.1038/nm953
   PubMed Web of Science ®Google Scholar
• Nanbakhsh A, Pochon C, Amsellem S, Pittari G, Tejchman A, Bourhis JH, Chouaib S. Enhanced cytotoxic activity of ex vivo-differentiated human natural killer cells in the presence of HOXB4. J Immunother 2014; 37:278-82; PMID:24810639; https://doi.org/10.1097/CJI.0000000000000039
   PubMed Web of Science ®Google Scholar
• Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, et al. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nat Commun 2016; 7:12475; PMID:27534895; https://doi.org/10.1038/ncomms12475
   PubMed Web of Science ®Google Scholar
• Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112:568-75; PMID:18523148; https://doi.org/10.1182/blood-2007-10-118331
   PubMed Web of Science ®Google Scholar
• Cany J, van der Waart AB, Spanholtz J, Tordoir M, Jansen JH, van der Voort R, Schaap NM, Dolstra H. Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology 2015; 4:e1017701; PMID:26140247; https://doi.org/10.1080/2162402X.2015.1017701
   PubMed Web of Science ®Google Scholar
• Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 2006; 108:3824-33; PMID:16902150; https://doi.org/10.1182/blood-2006-04-020198
   PubMed Web of Science ®Google Scholar
• Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203:1033-43; PMID:16606675; https://doi.org/10.1084/jem.20052507
   PubMed Web of Science ®Google Scholar
• Ahn YO, Blazar BR, Miller JS, Verneris MR. Lineage relationships of human interleukin-22-producing CD56+ RORgammat+ innate lymphoid cells and conventional natural killer cells. Blood 2013; 121:2234-43; PMID:23327921; https://doi.org/10.1182/blood-2012-07-440099
   PubMed Web of Science ®Google Scholar
• Rak GD, Mace EM, Banerjee PP, Svitkina T, Orange JS. Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse. PLoS Biol 2011; 9:e1001151; PMID:21931536; https://doi.org/10.1371/journal.pbio.1001151
   PubMed Web of Science ®Google Scholar
• Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9; PMID:9486650; https://doi.org/10.1038/35869
   PubMed Web of Science ®Google Scholar
• Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci U S A 2008; 105:6696-701; PMID:18448674; https://doi.org/10.1073/pnas.0802736105
   PubMed Web of Science ®Google Scholar
• Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998; 95:5199-204; PMID:9560253; https://doi.org/10.1073/pnas.95.9.5199
   PubMed Web of Science ®Google Scholar
• Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci U S A 2003; 100:14151-6; PMID:14612578; https://doi.org/10.1073/pnas.1835830100
   PubMed Web of Science ®Google Scholar
• Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987; 51:813-9; PMID:3315233; https://doi.org/10.1016/0092-8674(87)90104-8
   PubMed Web of Science ®Google Scholar
• Lehmann D, Spanholtz J, Sturtzel C, Tordoir M, Schlechta B, Groenewegen D, Hofer E. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential. PloS One 2014; 9:e87131; PMID:24498025; https://doi.org/10.1371/journal.pone.0087131
   PubMed Web of Science ®Google Scholar
• Boieri M, Ulvmoen A, Sudworth A, Lendrem C, Collin M, Dickinson AM, Kveberg L, Inngjerdingen M. IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo. Oncoimmunology 2017; 6:e1274478; PMID:28405496; https://doi.org/10.1080/2162402X.2016.1274478
   PubMed Web of Science ®Google Scholar
• Orr MT, Wu J, Fang M, Sigal LJ, Spee P, Egebjerg T, Dissen E, Fossum S, Phillips JH, Lanier LL. Development and function of CD94-deficient natural killer cells. PloS One 2010; 5:e15184; PMID:21151939; https://doi.org/10.1371/journal.pone.0015184
   PubMed Web of Science ®Google Scholar
• Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Marcucci G, et al. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. J Immunol 2009; 183:4968-74; PMID:19801519; https://doi.org/10.4049/jimmunol.0900907
   PubMed Web of Science ®Google Scholar
• Ponzetta A, Benigni G, Antonangeli F, Sciume G, Sanseviero E, Zingoni A, Ricciardi MR, Petrucci MT, Santoni A, Bernardini G. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res 2015; 75:4766-77; PMID:26438594; https://doi.org/10.1158/0008-5472.CAN-15-1320
   PubMed Web of Science ®Google Scholar
• Mayol K, Biajoux V, Marvel J, Balabanian K, Walzer T. Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. Blood 2011; 118:4863-71; PMID:21911833; https://doi.org/10.1182/blood-2011-06-362574
   PubMed Web of Science ®Google Scholar
• Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 2010; 341:37-58; PMID:20369317; https://doi.org/10.1007/82_2010_20
   PubMed Web of Science ®Google Scholar
• Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002; 71:173-83; PMID:11818437
   PubMed Web of Science ®Google Scholar
• Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K, et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42:443-56; PMID:25786176; https://doi.org/10.1016/j.immuni.2015.02.008
   PubMed Web of Science ®Google Scholar